|
Based in Illinois, Canavan Research Illinois is devoted to
saving all the victims of Canavan disease. Although fatal, as a rare disease, Canavan receives limited government funding,
and we rely on private donations to fund life-saving medical research. By helping us to fund cutting-edge research we are
giving these highly social, loving children a chance to have a future. Our efforts have resulted in the development of an
improved gene replacement therapy. This new approach is expected to yield a greater benefit for the victims of Canavan disease,
improving their quality of life. (See Media Section for full details)
We are a major contributor to the ongoing Gene
Therapy Trial for Canavan Disease currently at Cooper Health System, a division of Robert Wood Johnson Hospitals, Camden,
N.J. This trial is led by the world's leading researcher in gene therapy for Canavan disease, Paola Leone, Ph.D. We are also
funding Evan Snyder, M.D., Ph.D. (a leading researcher in the field of stem cells) at Harvard Institutes of Medicine, as well
as Dr. Morris Baslow (a renowned expert in Canavan disease) at The Center For Neurochemistry. Dr. Baslow is collaborating
with researchers at Kyoto University in Japan to develop a non-invasive drug therapy to improve the lives of the children
battling Canavan disease. Because Canavan serves as a model for other neurological diseases, our advancements can also benefit
millions suffering from debilitating neurological diseases such as ALS, Parkinson's, Alzheimer's, Multiple Sclerosis, and
stroke.
In addition to gene therapy, we are also funding groundbreaking research in the field of stem cells. Canavan
children may be among the first to benefit from the great potential stem cells have to repair brain damage. We also support
research to develop a pharmacological approach towards halting the devastation of this disease while researchers are racing
for a cure. The benefits of our research also offers hope to other neurological diseases and stroke.
|
